Dan Liu
Direktor/Vorstandsmitglied bei JIANGSU HUALAN NEW PHARMACEUTICAL MATERIAL CO.,LTD.
Profil
Dan Liu is an Independent Director at Jiangsu Hualan New Pharmaceutical Material Co., Ltd., a Director at Genfleet Therapeutics (Shanghai), Inc., and a Director at Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
He is also a Member-Supervisory Board at Innolake Pharmaceuticals (Hangzhou) Co., Ltd.
Dr. Liu previously worked as a Director at GemPharmatech Co., Ltd.
from 2019 to 2023.
He holds a doctorate degree from Yale University.
Aktive Positionen von Dan Liu
Unternehmen | Position | Beginn |
---|---|---|
JIANGSU HUALAN NEW PHARMACEUTICAL MATERIAL CO.,LTD. | Direktor/Vorstandsmitglied | 16.10.2018 |
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. Medical SpecialtiesHealth Technology Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. is a private company that manufactures medical equipment. The company is based in Wuxi, China. The Chinese company was founded in 1999. The CEO is Qing Song Sheng. | Direktor/Vorstandsmitglied | - |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | Direktor/Vorstandsmitglied | - |
Innolake Pharmaceuticals (Hangzhou) Co., Ltd.
Innolake Pharmaceuticals (Hangzhou) Co., Ltd. Pharmaceuticals: MajorHealth Technology Innolake Pharmaceuticals (Hangzhou) Co., Ltd. is a company based in Hangzhou, China that engages in the development and commercialization of therapeutic drugs for tumors and immune system diseases. The Chinese company was founded in 2020 by Ru Lei Chen and Ming De Xia, with Ming De Xia serving as the CEO since 2020. | Direktor/Vorstandsmitglied | 25.03.2021 |
Ehemalige bekannte Positionen von Dan Liu
Unternehmen | Position | Ende |
---|---|---|
GEMPHARMATECH CO., LTD. | Direktor/Vorstandsmitglied | 20.10.2023 |
Ausbildung von Dan Liu
Yale University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
JIANGSU HUALAN NEW PHARMACEUTICAL MATERIAL CO.,LTD. | Process Industries |
GEMPHARMATECH CO., LTD. | Health Technology |
Private Unternehmen | 3 |
---|---|
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | Commercial Services |
Innolake Pharmaceuticals (Hangzhou) Co., Ltd.
Innolake Pharmaceuticals (Hangzhou) Co., Ltd. Pharmaceuticals: MajorHealth Technology Innolake Pharmaceuticals (Hangzhou) Co., Ltd. is a company based in Hangzhou, China that engages in the development and commercialization of therapeutic drugs for tumors and immune system diseases. The Chinese company was founded in 2020 by Ru Lei Chen and Ming De Xia, with Ming De Xia serving as the CEO since 2020. | Health Technology |
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. Medical SpecialtiesHealth Technology Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. is a private company that manufactures medical equipment. The company is based in Wuxi, China. The Chinese company was founded in 1999. The CEO is Qing Song Sheng. | Health Technology |